CD274 and hepatocellular carcinoma: A Phase 1/2 study (NCT04612504) is currently ongoing to test the safety, tolerability and efficacy of SynOV1.1, either alone or in combination with the anti-PD-L1 antibody atezolizumab in 45 advanced HCC patients.